The global inhibitor of nuclear factor-kappa b kinase subunit beta or IKK? market is expected to grow at a significant CAGR during the forecast period (2022-2028). IKK?, or inhibitor of nuclear factor kappa-B kinase subunit beta, is a protein encoded by the IKBKB (inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta) gene in humans. The IKK?, a particular regulator of nuclear factor-B (NF-B), is thought to be a promising target for developing new medications to treat rheumatoid arthritis and cancer. 

IKK? has been proven to be a therapeutic target for a variety of clinical illnesses, including cancer and chronic inflammatory diseases. Inflammation is present in a wide range of disorders and circumstances, including diseases. Allergies, asthma, autoimmune disorders, celiac disease, glomerulonephritis, hepatitis, inflammatory bowel disease, preperfusion damage, and transplant rejection are only few of the conditions that can occur. The rising prevalence of cancer across the globe is contributing to the growth of the global IKK? market.  Breast and lung cancers were the most frequent cancers globally in 2020, accounting for 12.5% and 12.2% of all new cases, respectively. With 1.9 million new cases in 2020, colorectal cancer was the third most frequent cancer, accounting for 10.7% of all new cases. Lung cancer was the most frequent cancer in men globally in 2020, accounting for 15.4% of all new cases diagnosed. Lung, prostate, and colorectal cancers accounted for 41.9% of all cancer cases (excluding non-melanoma skin cancer). Other prevalent tumours that contributed more than 5% were stomach and liver cancers. Breast cancer was the most common cancer among women globally in 2020, accounting for 25.8% of all new cases diagnosed. Breast, colorectal, and lung cancers accounted for 44.5% of all cancer cases (excluding non-melanoma skin cancer). Cervical cancer was the fourth most frequent cancer among women in 2020, accounting for 6.9% of all new cases diagnosed.

Market Coverage

• The market number available for – 2021-2028

• Base year- 2021

• Forecast period- 2022-2028

• Segment Covered- 

o By Product 

o By Application 

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape:  Daiichi Sankyo Co Ltd., and EntreChem, S.L., among others. 

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How are players addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta Market Report by Segment

By Product 

• TLX-1423

• IMD-0560

• EC-70124

• Others

By Application

• Colorectal Cancer

• Pancreatic Cancer

• Prostate Cancer

• Others

Global Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta Market Report by Region

North America       

• US

• Canada

Europe

• Germany

• UK

• France

• Spain

• Italy

• Rest of Europe

Asia-Pacific    

• China

• Japan

• India

• Rest of Asia-Pacific

Rest of the World

• Latin America

• Middle East and Africa